Q3 2020 Targovax ASA Earnings Call Transcript
Ladies and gentlemen, welcome to the third quarter presentation of Targovax' results. My name is Ãystein Soug, I'm the CEO of Targovax. And with me today in the office or should I say studio, we have Torbjørn Furuseth, the CFO. And also calling in from London, we have Magnus Jäderberg, our Chief Medical Officer.
I will take you through the introduction. Torbjørn will go through the finances. And last but not least, Magnus will take you through the clinical program with focus on colorectal, mesothelioma and melanoma.
Before I start, I just want to remind you that it's possible to send in questions through the web page, which we will answer after -- right after this presentation is concluded.
Now in Targovax, we aim to unlock the clinical benefit of cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Our lead product is ONCOS-102, which we direct towards and try to combine with checkpoint inhibitors. And we have encouraging data, not only in combination with checkpoint
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
